Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37972333)
Watch
English
Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?
scientific article published on December 2011
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
title
Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
main subject
cystic fibrosis
0 references
author
Donald R. VanDevanter
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
Alan R. Smyth
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
author name string
David Lo
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
Patrick Flume
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
publication date
1 December 2011
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
published in
Respiratory Medicine
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
volume
105 Suppl 2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
page(s)
S9-17
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
cites work
CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival estimates for adults with cystic fibrosis born in the United Kingdom between 1947 and 1967. The UK Cystic Fibrosis Survey Management Committee
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cystic fibrosis mortality and survival in the UK: 1947-2003
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prediction of Mortality in Patients with Cystic Fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adherence with tobramycin inhaled solution and health care utilization
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Microbiological and immunologic considerations with aerosolized drug delivery
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0954-6111(11)70022-1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
PubMed publication ID
22208548
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit